Argenx extends gains after analyst target hikes, shares outperform biotech peers
Published on 06/24/2026 at 07:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 07:08.
Argenx SE (NL0010832176) stays on the radar of US investors after a marked analyst push. The Nasdaq-listed antibody specialist benefits from fresh price target increases by Wells Fargo and Stifel, while its shares recently touched a 20-day high according to a Yahoo Finance summary.Yahoo Finance market overview
What the latest analyst calls say
Wells Fargo raised its price target on Argenx to 1,291 US dollars from 1,260 dollars and reiterated an Overweight rating on the shares, underscoring its constructive stance on the biotech name in Nasdaq trading.Intellectia summary of analyst moves
Stifel followed with a target increase to 1,255 dollars from 1,222 dollars and kept a Buy rating, adding a second supportive voice from the US broker community on the same stock.Stifel target change recap
How Argenx shares have traded recently
According to a recent performance snapshot, Argenx shares rose by around 3.0 percent over one session and reached a 20-day high at the same time, a move that came as the Nasdaq-100 index declined by roughly 2.6 percent and the S&P 500 by nearly 1.0 percent.Short-term performance data
This divergence highlights that the stock has recently outperformed both broader US equity benchmarks and several large-cap biotech peers such as Vertex Pharmaceuticals and Regeneron Pharmaceuticals, which have shown more muted moves in the same window per Nasdaq data.Nasdaq quote and peer overview
All news and analysis on the Argenx shares
Price history, research views and corporate disclosures on Argenx are bundled on the topic page and in the company’s investor relations section.
How Argenx generates its revenue
Argenx centers its business on antibody-based therapies for autoimmune diseases and certain cancers, with its commercial flagship efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo, targeting generalized myasthenia gravis and other indications via neonatal Fc receptor modulation.Company information on efgartigimod
Where the stock trades today
The Argenx shares (NL0010832176) trade on Nasdaq under the ticker ARGX; the most recent observable price was 404.50 US dollars on 2026-06-23, 21:59, according to Nasdaq data.
Key data on the Argenx shares
- Company: Argenx SE
- ISIN: NL0010832176
- WKN: A2AS1A
- Ticker: ARGX
- Trading venue: NASDAQ
- Price (as of 2026-06-23, 21:59): 404.50 USD
- Market cap: 23.5 billion USD (as of 2026-06-23)
- Sector / industry: Biotechnology / Biopharmaceuticals
- Index membership: NASDAQ-100
- Next earnings date: 2026-07-25
This text is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any securities. Figures and dates are based on publicly available sources and may change.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
